Cargando…
A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy
Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which was treated using high dose prednisolone. He develop...
Autores principales: | Takahashi, Hidenori, Koiwa, Tomohiro, Fujita, Akira, Suzuki, Takayuki, Tagashira, Amane, Iwasaki, Yoshinobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260580/ https://www.ncbi.nlm.nih.gov/pubmed/32489850 http://dx.doi.org/10.1016/j.rmcr.2020.101097 |
Ejemplares similares
-
Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors
por: Kurozumi, Atsumasa, et al.
Publicado: (2021) -
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
por: Kalmuk, James, et al.
Publicado: (2020) -
Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma
por: Akagi, Yu, et al.
Publicado: (2020) -
COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report
por: Ramos-Ruperto, Luis, et al.
Publicado: (2021) -
Hemophagocytic Lymphohistiocytosis
por: Kaçar, Ayşe Gonca, et al.
Publicado: (2022)